Log In
Print
BCIQ
Print
Print this Print this
 

orteronel (TAK-700)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionNon-steroidal, selective inhibitor of cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17)
Molecular Target Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17)
Mechanism of ActionCytochrome P450 17alpha-hydroxylase/C17,20 lyase (CYP17) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC) in chemotherapy-naïve patients; Treat metastatic castration-resistant prostate cancer (CRPC) that has progressed during or following docetaxel-based therapy; Treat non-metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today